Literature DB >> 33285579

The History of Psychedelics in Psychiatry.

David E Nichols1, Hannes Walter2.   

Abstract

Initial interest in the value of psychedelic drugs ("psychotomimetics") in psychiatry began in the early 20th century, with explorations of the possibility that mescaline or peyote could produce psychosis-like effects. Over time, interest was focused on whether the effects of psychedelics could inform as to the underlying basis for psychiatric disorders. As research continued, and especially after the discovery of LSD in 1943, increasing interest in a role for psychedelics as adjuncts to psychotherapy began to evolve and became the major focus of work with psychedelics up to the present day. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 33285579     DOI: 10.1055/a-1310-3990

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

Review 1.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

2.  Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland.

Authors:  Ahmed Al-Imam; Marek A Motyka; Zuzanna Witulska; Manal Younus; Michał Michalak
Journal:  Int J Environ Res Public Health       Date:  2022-05-29       Impact factor: 4.614

Review 3.  Serotonergic Psychedelics in Neural Plasticity.

Authors:  Kacper Lukasiewicz; Jacob J Baker; Yi Zuo; Ju Lu
Journal:  Front Mol Neurosci       Date:  2021-10-12       Impact factor: 6.261

Review 4.  Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs.

Authors:  Enzo Tagliazucchi
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

5.  How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Authors:  Manon van den Berg; Igor Magaraggia; Rudy Schreiber; Todd M Hillhouse; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2022-03-29       Impact factor: 4.415

6.  Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Benedikt Pulver; Hannes M Schwelm; Kyla Whitelock; Alexander Stratford; Volker Auwärter; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2022-05-29       Impact factor: 3.234

7.  Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.

Authors:  Hitoshi Sakurai; Kengo Yonezawa; Hideaki Tani; Masaru Mimura; Michael Bauer; Hiroyuki Uchida
Journal:  Pharmacopsychiatry       Date:  2022-01-19       Impact factor: 2.544

Review 8.  Catalysts for change: the cellular neurobiology of psychedelics.

Authors:  Matthew I Banks; Zarmeen Zahid; Nathan T Jones; Ziyad W Sultan; Cody J Wenthur
Journal:  Mol Biol Cell       Date:  2021-06-01       Impact factor: 4.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.